Interim Valeant CEO Schiller expects to stick to the script–and that means being ‘boring’ in 2016

Carly Helfand When Valeant installed former CFO Howard Schiller as interim CEO earlier this week, it said the board would continue to work closely with Schiller to implement company ...

AbbVie nabs quick FDA review for Viekira Pak in genotype 1b patients

Emily Wasserman AbbVie knows that focusing on untapped niches is key to its hep C success, targeting small populations of patients to increase market share for its blockbuster-in-the-making, ...

Another Chinese biopharma lines up for a billion-dollar IPO

Damian Garde Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $ 1 billion, according to reports, joining a slew of local biopharma companies headed ...

German generics maker mulls $1.1B sale amid pharma’s M&A frenzy: Reuters

Emily Wasserman It's been a banner year for pharma M&A, and German generics maker Dermapharm is wise to the trend. The company is planning a €1 billion ($ 1.1 billion) ...

KaloBios files for bankruptcy in the shadow of Shkreli’s arrest

Damian Garde KaloBios was days away from shutting its doors for good when controversial entrepreneur Martin Shkreli swooped in to keep the company afloat last month. Now, with its purported ...
Page 17 of 17« First...10...1314151617
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS